NDA BLA and PMA

NDA, BLA, and PMA are three types of applications submitted by pharmaceutical and biotech companies to regulatory authorities, such as the U.S. Food and Drug Administration (FDA), for approval to market and sell a drug or biologic product in the United States. Here is a brief overview of each:

1. New Drug Application (NDA): An NDA is submitted to the FDA for a new drug that has not been approved before. It contains all the data from preclinical studies and clinical trials to demonstrate the safety and effectiveness of the drug for its intended use. The NDA also includes information on the drug’s pharmacology, manufacturing, and proposed labeling, as well as any adverse events associated with the drug. Once the FDA reviews the NDA, it can approve the drug for marketing and sale in the United States.
2. Biologics License Application (BLA): A BLA is similar to an NDA, but it is for a biologic product, which is typically derived from living organisms, such as vaccines, blood components, and gene therapies. The BLA must contain data from preclinical and clinical studies to demonstrate the safety, purity, and potency of the biologic product, as well as information on its manufacturing and proposed labeling.
3. Premarket Approval (PMA): A PMA is required for medical devices that are deemed to be high risk by the FDA, such as implantable devices and life-sustaining devices. The PMA contains data from clinical trials to demonstrate the safety and effectiveness of the device, as well as information on its design, manufacturing, and proposed labeling. The FDA reviews the PMA and can approve the device for marketing and sale in the United States.

In summary, NDA, BLA, and PMA are all regulatory applications that must be submitted to the FDA to obtain approval to market and sell a drug or medical device in the United States. The specific type of application depends on the type of product being submitted for approval.

You may be interested in the programs below: